LOGC•benzinga•
LogicBio Therapeutics's Return On Capital Employed Insights
Summary
According to data from Benzinga Pro, during Q2, LogicBio Therapeutics's (NASDAQ:LOGC) reported sales totaled $3.20 million. Despite a 24.29% increase in earnings, the company posted a loss of $5.04 million.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 12, 2022 by benzinga